Second-lineZofran

Ondansetron

5-HT3 receptor antagonist

Second-line antiemetic for hyperemesis gravidarum.

OralIVODT (wafer)

First-line for

  • Hyperemesis gravidarum unresponsive to 1st-line antiemetics

Mechanism

Blocks central & peripheral 5-HT3 receptors in CTZ and gut → ↓ vomiting reflex.

“After 10 wks”

  • Avoid before 10 weeks if possible (cleft palate signal, NNH ~1/1000)
  • OK after 10 weeks
  • Watch QT — avoid with other QT-prolonging drugs

Dosing

Oral / IV
4–8 mg q8h
Max
16 mg/day (QT risk above)

Contraindications

  • AbsoluteCongenital long QT
  • CautionCombine with apomorphine — hypotension

Side effects

  • Constipation, headache
  • QT prolongation
  • Rare: serotonin syndrome with SSRIs

Fetal & maternal notes

  • Small absolute ↑ risk of cleft palate (use after 10 wks ideally).
  • No ↑ in overall malformation rate.
  • Safe in breastfeeding.

Key interactions

  • QT-prolonging drugs

    Avoid

    Additive QT — avoid

  • SSRIs / SNRIs

    Caution

    Serotonin syndrome (rare)

Clinical pearls

  • 💡 1st-line: cyclizine, promethazine, prochlorperazine.
  • 💡 Always assess hydration, ketosis, weight loss in HG.

Content last reviewed: REPLACE_ME (e.g. 2026-07)

Spotted something out of date? See our disclaimer or use Report an Error above.

For educational use only

Not medical advice. Verify dosing against the BNF and your local trust guidelines before prescribing.